CAM Intervention for Rheumatoid Arthritis

Information

  • Research Project
  • 7490102
  • ApplicationId
    7490102
  • Core Project Number
    R21AT004312
  • Full Project Number
    5R21AT004312-02
  • Serial Number
    4312
  • FOA Number
    RFA-AT-06-05
  • Sub Project Id
  • Project Start Date
    9/1/2007 - 16 years ago
  • Project End Date
    6/30/2010 - 13 years ago
  • Program Officer Name
    PONTZER, CAROL H
  • Budget Start Date
    7/1/2008 - 15 years ago
  • Budget End Date
    6/30/2010 - 13 years ago
  • Fiscal Year
    2008
  • Support Year
    2
  • Suffix
  • Award Notice Date
    7/3/2008 - 15 years ago
Organizations

CAM Intervention for Rheumatoid Arthritis

[unreadable] DESCRIPTION (provided by applicant): Complementary and alternative medicines(CAMs) are widely used for treatment of inflammatory diseases. A subset of these CAMs include microbial products, protobiotics, and live and killed bacteria. Recent work using a Salmonella-based CAM that expresses colonization factor antigen I (CFA/I) fimbriae from enterotoxigenic E. coli can treat experimental autoimmune encephalomyelitis (EAE). Mode of action by the Salmonella-CFA/I CAM is attributed to its ability to suppress innate inflammatory responses, as well by immune deviation to promote T helper (Th) cell 2 bias. Similar protective therapeutic intervention was also obtained with just the Salmonella vector, but efficacy was not as potent as that obtained using the Salmonella-CFA/I. Subsequent analysis revealed that oral dosing with either Salmonella CAM could induce regulatory CD25+ CD4+ T (Treg) cells, and the difference in protection was attributed to the potency of the induce Treg cells. These findings led us to speculate that the Salmonella-CFA/I CAM possesses anti-inflammatory properties that may be applicable to treating arthritis. Thus, the hypothesis to be tested in this application is that oral administration with Salmonella CAMs, specificially, Salmonella-CFA/I, will reduce disease severity and limit disease progression in an experimental rheumatoid arthritis (RA) model. The widely used type II collagen-induced arthritis (CIA) murine model for RA will be tested using DBA/1 and C57BL/6 mice. To test this hypothesis, two Specific Aims are proposed. Studies in Specific Aim 1 will determine the effectiveness of Salmonella CAMs treatment upon CIA. Studies in Specific Aim 2 will determine which regulatory T cell subset is responsible for protection against CIA and determine which inflammatory Teff cell subset is diminished. These studies will provide the basis for future development of strategies to regulate RA. This application is responsive to RFA-AT-06-005: "Mechanisms of Immune Modulation" by addressing the requested research areas in understanding CAMs' mechanisms of action upon the induction and expansion of T cell regulatory populations. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE
  • Activity
    R21
  • Administering IC
    AT
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    173338
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    213
  • Ed Inst. Type
    EARTH SCIENCES/RESOURCES
  • Funding ICs
    NCCAM:173338\
  • Funding Mechanism
  • Study Section
    ZAT1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MONTANA STATE UNIVERSITY (BOZEMAN)
  • Organization Department
    VETERINARY SCIENCES
  • Organization DUNS
  • Organization City
    BOZEMAN
  • Organization State
    MT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    59717
  • Organization District
    UNITED STATES